Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
JIN MEDICAL INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
20.08. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
16.07. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
16.07. | Jin Medical International Ltd.: Jin Medical Launches Production at Plant No. 3, Accelerating Global Delivery from the Chuzhou Manufacturing Facility | 1 | GlobeNewswire (USA) | ||
24.06. | Jin Medical International ernennt Dr. James Jiayuan Tong zum unabhängigen Direktor | 6 | Investing.com Deutsch | ||
24.06. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
17.06. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
06.05. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
06.05. | Jin Medical International Ltd. - Nasdaq Minimum Bid Price Non-Compliance | 80 | GlobeNewswire (Europe) | Changzhou City, China, May 06, 2025 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (NASDAQ: ZJYL) (the "Company") today announced that on May 2, 2025, it received a deficiency letter (the "Notice")... ► Artikel lesen | |
25.04. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,103 | -1,90 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
PLUS THERAPEUTICS | 0,415 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria | HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,689 | -2,13 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services | ||
PING AN HEALTHCARE | 2,254 | +1,30 % | Ping An Healthcare and Technology Company Limited: Ping An Good Doctor (1833.HK) Reports Solid Interim Results with Steady Revenue and Profit Growth | HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June... ► Artikel lesen | |
MOUNTAIN VALLEY MD | 0,015 | +13,64 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
CO-DIAGNOSTICS | 0,354 | +0,57 % | Co-Diagnostics platziert Aktien im Wert von 3,8 Millionen US-Dollar | ||
VERU | 3,420 | -7,07 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
CYTOSORBENTS | 0,772 | -0,13 % | Cytosorbents Corp - 8-K, Current Report | ||
AMBU | 13,040 | -0,08 % | Ambu A/S: Interim Report For Q3 2024/25 | 22.8.2025 07:00:01 CEST | Ambu A/S |
Interim report (Q1 and Q3)
In the third quarter of the 2024/25 financial year, Ambu delivered 12.0% organic revenue growth and an 11.3% EBIT margin before special... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update | Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines... ► Artikel lesen | |
VOLITIONRX | 0,640 | 0,00 % | VolitionRX stock holds steady as Benchmark reiterates rating | ||
SIEMENS HEALTHINEERS | 47,260 | -0,78 % | Kursphantasien steigen - AJN Resources, HOCHTIEF, Siemens Healthineers | Nach den Kursrücksetzern der US-Börsen Anfang September notieren diese bereits wieder am Allzeithoch bzw. haben - wie der S & P 500 - bereits mit gestrigem Tage neue Allzeithochs erreichen können. Dagegen... ► Artikel lesen | |
FRESENIUS | 47,500 | +0,81 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Fresenius auf "Overweight" belassen. Die Aktie steht zudem auf der "Analyst Focus List" der US-Bank. Die Aktienkurse der europäischen Medizinunternehmen... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 43,410 | +1,71 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
GERRESHEIMER | 43,300 | +0,28 % | GERRESHEIMER wird zunächst zur Spielwiese | Die Kurskorrektur ist massiv ausgefallen. Mit der Übernahme von Bormioli Pharma ist GERRESHEIMER angreifbar geworden, weil der Kaufpreis umfangreich fremdfinanziert wurde. Was rechnen sich die Investoren... ► Artikel lesen |